Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 45 citing Holst: The incretin approach for diabetes treatment. (0.12 sec) 

[PDF] Twelve− week Monotherapy with the DPP− 4 Inhibitor Vildagliptin Improves Glycemic …


D Holmes - Horm Metab Res, 2006 - rima.org
The incretin hormones ± glucose−dependent insulinotropic poly− peptide
(GIP) and particularly glucagon−like peptide−1 (GLP−1) ± have been
reported to exert multiple metabolic effects that con− tribute to the ...
Cited by 120 - Related articles - View as HTML - BL Direct - All 4 versions

Type 2 diabetes—therapy with dipeptidyl peptidase IV inhibitors


HU Demuth, CHS McIntosh, RA Pederson - BBA-Proteins and Proteomics, 2005 - Elsevier
This was demonstrated in rat applying the specific DP IV inhibitor isoleucyl
thiazolidine. It was published in 1996 for the first time that a specific DP IV
inhibitor in a given dose was able to completely block glucagon-like ...
Cited by 79 - Related articles - All 3 versions

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left …

- physiology.org
LA Nikolaidis, D Elahi, YT Shen, RP Shannon - American Journal of Physiology- Heart and Circulatory …, 2005 - Am Physiological Soc
We have shown previously that the glucagon-like peptide-1 (GLP-1)-(7–36) amide
increases myocardial glucose uptake and improves left ventricular (LV) and
systemic hemodynamics in both conscious dogs with pacing-induced dilated ...
Cited by 39 - Related articles - BL Direct - All 5 versions

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes


RE Pratley, A Salsali - Current Medical Research and Opinion®, 2007 - informahealthcare.com
University of Vermont College of Medicine, Burlington, VT, USA ... Address for
correspondence: Richard E. Pratley, MD, Professor of Medicine, Director –
Diabetes & Metabolism Translational Medicine Unit, Department of Medicine, ...
Cited by 29 - Related articles - BL Direct - All 4 versions

PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated …

- snupharm.ac.kr [PDF] 
S Lee, YS Youn, SH Lee, Y Byun, KC Lee - Diabetologia, 2006 - Springer
Abstract Aims/hypothesis: The rapid degradation and clearance of glucagon-like
peptide-1 (GLP-1) by the en- zymes dipeptidyl peptidase-IV and neutral
endopeptidase 24.11 are the main impediments to the development of GLP-1 as ...
Cited by 19 - Related articles - BL Direct - All 7 versions

Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor


C Parthier, M Kleinschmidt, P Neumann, R … - Proceedings of the National Academy of Sciences, 2007 - National Acad Sciences
Incretins, endogenous polypeptide hormones released in response to food intake,
potentiate insulin secretion from pancreatic β cells after oral glucose
ingestion (the incretin effect). This response is signaled by the two ...
Cited by 19 - Related articles - BL Direct - All 9 versions

Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of …


RK Campbell - The Annals of pharmacotherapy, 2007 - Harvey Whitney Books
Published Online, 26 December 2006, www.theannals.com, DOI 10.1345/aph.1H459.
The Annals of Pharmacotherapy: Vol. 41, No. 1, pp. 51-60. DOI 10.1345/aph.1H459
© 2007 Harvey Whitney Books Company. ... OBJECTIVE: To review advances in ...
Cited by 18 - Related articles - BL Direct - All 5 versions

Inhibitors of Dipeptidyl Peptidase IV-Recent Advances and Structural Views


D Hunziker, M Hennig, JU Peters - Current Topics in Medicinal Chemistry, 2005 - ingentaconnect.com
Abstract: Prevalence of type 2 diabetes has increased dramatically in the last
decades. Current medicines are not yet capable to efficiently prevent or reverse
progression of the disease and its associated comorbidities. As a ...
Cited by 13 - Related articles - BL Direct - All 3 versions

Incretin-based therapies: mimetics versus protease inhibitors


PL Brubaker - Trends in Endocrinology & Metabolism, 2007 - Elsevier
The physiological incretins, glucose-dependent insulinotropic polypeptide (GIP)
and glucagon-like peptide-1 (GLP-1), lower blood glucose levels through multiple
mechanisms, including enhancement of glucose-stimulated insulin secretion. ...
Cited by 13 - Related articles - All 6 versions

DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells


K Masur, F Schwartz, F Entschladen, B … - Regulatory peptides, 2007 - Elsevier
The glucagon-like peptides-1 and -2 (GLP-1 and -2) are co-secreted after food
intake from intestinal L cells. Since both peptides are rapidly degraded by
dipeptidyl peptidase-IV (DPPIV), research is focused on the development of ...
Cited by 10 - Related articles - All 4 versions


Result Page: 

1

2

3

4

5

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google